Mutual of America Capital Management LLC reduced its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) ...

Equities researchers at Zacks Research issued their FY2024 earnings per share (EPS) estimates for Blueprint Medicines in a ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

马萨诸塞州剑桥市 - 根据最近的SEC文件披露，Blueprint Medicines Corp (NASDAQ:BPMC)的董事Lonnel Coats于11月20日和21日执行了一系列股票交易，其中包括总计约187万美元的销售。

At this time, I would like to welcome everyone to the Blueprint Medicines Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Thank you. Jenna Cohen, you may begin your ...

The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug ...

Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their ...